What is VKA (Vitamin K Antagonist)?
VKA stands for Vitamin K Antagonist, a class of oral anticoagulant medications that work by interfering with the vitamin K cycle to reduce the synthesis of functional vitamin K-dependent clotting factors (factors II, VII, IX, and X, as well as proteins C and S). 1
Mechanism of Action
VKAs inhibit vitamin K epoxide reductase (VKOR), the enzyme that generates the active hydroquinone form of vitamin K 2. By blocking this enzyme:
- The vitamin K redox cycle is disrupted
- Hepatic production of vitamin K-dependent clotting factors is reduced
- Anticoagulation is achieved through decreased synthesis of functional coagulation proteins 1, 2
The most commonly used VKA is warfarin, which has been the gold standard in oral anticoagulation for over 50 years 3, 1.
Clinical Characteristics
Therapeutic Monitoring
- Target INR range: 2.0-3.0 (target 2.5) for most indications 1
- Higher targets (INR 3.0, range 2.5-3.5) are used for mechanical mitral valves or double valve replacements 4
- Requires frequent INR monitoring due to narrow therapeutic window 1
Key Management Points
Initiation:
- When starting VKA therapy, overlap with parenteral anticoagulation (heparin, LMWH, or fondaparinux) for ≥5 days until INR is 2.0-3.0 for 2 consecutive days 3
- Initial warfarin dosing: 10 mg for younger healthy patients, ≤5 mg for older patients 3
Discontinuation:
- Abrupt discontinuation is preferred over gradual tapering 1
Reversal:
- For major bleeding: four-factor prothrombin complex concentrate plus vitamin K 5-10 mg IV 1, 5
- For INR >10 without bleeding: oral vitamin K 1
Important Clinical Caveats
Limitations of VKAs:
- Narrow therapeutic index requiring frequent monitoring 1
- Significant inter-individual dose variability 6
- Multiple drug and food interactions 7
- Unpredictable pharmacokinetics 8
- Non-hemostatic effects: VKAs affect all vitamin K-dependent proteins, not just clotting factors, which can promote vascular calcification 9, 10
Common Pitfalls:
- Avoid concomitant antiplatelet agents unless specific high-risk situations exist (mechanical valves, acute coronary syndrome, recent coronary stents) 1
- Genetic polymorphisms in CYP2C9 and VKORC1 affect dosing requirements, though routine pharmacogenetic testing is not recommended 1, 6
- Renal dysfunction and body weight require dose adjustments for bridging agents, not VKAs themselves 1
Modern Context
VKAs are increasingly being replaced by direct oral anticoagulants (DOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban 7, 11, 8. DOACs offer:
- More predictable pharmacokinetics
- No routine monitoring required
- Fewer drug-food interactions
- Improved safety profile 7
However, VKAs remain essential for patients with mechanical heart valves, severe renal insufficiency (CrCl <25-30 mL/min), and in settings where DOACs are unavailable or unaffordable 4, 3, 4.